Trial of fibrate therapy in primary biliary cholangitis shows treatment is well tolerated

The results of the BEZURSO study, presented today, found that bezafibrate in combination with UDCA normalised prognostic markers of liver disease in patients with primary biliary cholangitis (PBC) with an inadequate response to UDCA. The study, presented at The International Liver Congress 2017 in Amsterdam, The Netherlands, showed that the bezafibrate and UDCA combination therapy was well tolerated, normalised prognostic biochemical parameters, improved fatigue and itching, and prevented progression of liver stiffness and ELF score, which are predictors of liver failure and mortality.1,2

PBC is a that can damage and eventually destroy bile ducts.3 It is an inflammatory condition which can lead to cirrhosis, and cancer.3 PBC affects mostly middle-aged women and may progress silently for years; over time, symptoms such as fatigue and itching (pruritus) emerge, often resulting in poor quality of life for .3 PBC is a disease that cannot be cured: there is no therapy that can stop its progression. A large proportion of patients respond to the administration of UDCA, which can significantly improve , and slow the destruction of bile ducts as well as disease progression.4,5 However, more than 30% of patients do not respond adequately to UDCA treatment, and thus remain at high risk of disease progression which may require a transplant, as well as reduced survival rates.6 Additional treatments for these patients are urgently needed.4,5

"This study is the first large randomised trial of fibrates in patients with PBC who had responded inadequately to UDCA," said Dr Christophe Corpechot, head of the Reference Center for Inflammatory Biliary Diseases, Paris, France, and lead author of the study. "The study provides evidence supporting the use of a combination of fibrates and UDCA in this population, with normalisation of liver function tests, improved symptoms and prevention of liver disease progression."

The BEZURSO study (Bezafibrate in Combination with Ursodeoxycholic Acid in Primary Biliary Cirrhosis) was a randomised, double-blind, placebo-controlled trial of bezafibrate for the treatment of PBC in 100 patients with an incomplete response to UDCA.7 Patients with an inadequate biochemical response to UDCA, as defined by the Paris-2 criteria, were randomised to two years of either bezafibrate 400 mg/day or placebo, in combination with UDCA 13-15 mg/kg/day. Normalisation of liver function tests was the primary endpoint.

The primary endpoint was reached in 15 (30%) patients in the bezafibrate group compared with no patients in the placebo group (p<0.0001). Alkaline phosphatase normalisation occurred in 67% of patients in the bezafibrate group compared with 0% in the placebo group. Fatigue and itching were significantly reduced in the bezafibrate group, as well as surrogate markers of liver fibrosis ( and ELF score). The rates of serious adverse events were similar in both groups. The rates of end-stage liver complications did not differ between the treatment groups (4% in both groups).

"This study could have an important impact on clinical practice, as it shows that patients with PBC who do not respond adequately to current treatment with UDCA, could obtain a notable benefit with additional bezafibrate therapy, a drug which is already used for the treatment of hypercholesterolaemia," said Prof Marco Marzioni, Professor of Gastroenterology, Università Politecnica delle Marche - "Ospedali Riuniti" University Hospital of Ancona, Italy and EASL Governing Board Member.


Explore further

Rituximab is not effective for the treatment of fatigue in primary biliary cholangitis

More information: Abstract: A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (BEZURSO) (LBO-01), The International Liver Congress 2017.

References:

1 Corpechot C, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198-208.
2 Mayo M, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549-57.
3 British Liver Trust. Primary biliary cholangitis/cirrhosis. Available from: www.britishlivertrust.org.uk/l … y-biliary-cirrhosis/. Last accessed: April 2017.
4 Dyson JK, et al. Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2015;12(3):147-58.
5 Beuers U, et al. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1):S25-S37.
6 Parés A. Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? Clin Liver Dis. 2014;3(2):29-33.
7 ClinicalTrials.gov. NCT Identifier: NCT01654731. Phase 3 study of bezafibrate in combination with ursodeoxycholic acid in primary biliary cirrhosis (BEZURSO). Available from: clinicaltrials.gov/ct2/show/study/NCT01654731. Last accessed: April 2017.
8 Lab Tests Online. Liver function tests. Last accessed: April 2017.

Provided by European Association for the Study of the Liver
Citation: Trial of fibrate therapy in primary biliary cholangitis shows treatment is well tolerated (2017, April 22) retrieved 26 January 2021 from https://medicalxpress.com/news/2017-04-trial-fibrate-therapy-primary-biliary.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
44 shares

Feedback to editors

User comments